The first lyophilized plasma in Europe
Grifols patents this process in Spain and develops a lyophilizer plus complementary devices in order to use plasma subsequently for therapeutic purposes.
The blood bank is born
Grifols opens the first private blood and plasma bank in Spain.
Plasmapheresis: a new way to collect plasma
Dr. Josep Antoni Grífols i Lucas develops this innovative technique, which allows reintroducing the donor's red blood cells immediately after extraction.
The first steps in fractionation
The first plasma fractionation plant in Spain begins operations.
A notable increase in production
Grifols opens a new production plant in Barcelona.
Very high standards of quality
With its production plant in Barcelona, Grifols becomes the first Spanish company to receive an FDA license for its installations and for its production of a biological product (albumin).
New plasma suppliers
Grifols acquires the US company SeraCare (currently Biomat) and its 43 donation centers.
Direct presence in US
Grifols acquires the assets of Alpha Therapeutic Corporation-Mitsubishi, including its plasma fractionation plant in Los Angeles, California.
FDA approval for the immune globulin (IG) plant in Barcelona. Listing on the Spanish stock exchange IBEX35.
A boom in the plasma industry
Grifols acquires Talecris Biotherapeutics to become the third largest manufacturer of plasma-derived medicines in the world. Listing on the NASDAQ exchange.
The Diagnostic Division grows
Acquisition of the Novartis diagnostics business unit.
Global leaders in transfusion medicine
Grifols acquires Hologic's NAT donor screening unit.
Grifols becomes the worldwide leader in plasma donation centers, with 190 centers in the US.